Advances in nucleotide-based P2Y₁ antagonism: implications for cardiovascular therapeutics.

Adenosine A2A and A2B Receptors as Therapeutic Targets in Cardiovascular Diseases: Mechanistic Insights and Clinical Prospects

Adenosine is a ubiquitous endogenous modulator that coordinates diverse physiological processes by binding to specific adenosine receptors (ARs). Among the four known AR subtypes, A2ARs and A2BRs are critical determinants of cardiovascular homeostasis. This narrative review comprehensively synthesizes current knowled...

Targeting an atypical G protein-coupled receptor signaling pathway for cardiac fibrosis therapy.

Cardiac fibrosis independently predicts adverse outcomes in heart failure (HF), yet no Food and Drug Administration-approved therapy directly targets fibrotic remodeling in the heart. To address this unmet clinical need, we used a multidimensional drug discovery pipeline centered on a human induced pluripotent stem cel...

Coumarins in hypertension management: from vascular signaling pathways to clinical perspectives.

Unraveling the Intricacies of G-Protein-Coupled Receptor Signaling in Cardiovascular Diseases: Novel Perspectives From Regulation to Therapeutic Targeting.

The contributions of class A, class B, and other GPCR families to cardiovascular physiology and pathology are discussed, emphasizing their relevance to the development of targeted interventions for hypertension, heart failure, arrhythmias, atherosclerosis, and related CVDs.

NLRP3 inflammasome in cardiovascular diseases: molecular mechanisms and advances in targeted drug research

The NLRP3 inflammasome plays a pivotal role in innate immune responses and has emerged as an important contributor to the pathogenesis of cardiovascular diseases (CVDs), including atherosclerosis, heart failure, myocardial infarction, and hypertension-related organ damage. Upon activation, NLRP3 promotes the maturation...

Translational Advances in GLP-1–Based Therapies for Cardiometabolic Disease

A narrative review summarizes the evolution of GLP–1–based therapies, highlights emerging dual and triple agonists, and discusses their mechanisms, clinical implications, and safety profiles.